JD Health International Inc. (HKG:6618)
59.30
-1.50 (-2.47%)
Nov 5, 2025, 9:45 AM HKT
JD Health International Revenue
JD Health International had revenue of 35.29B CNY in the half year ending June 30, 2025, with 30.17% growth. This brings the company's revenue in the last twelve months to 65.11B, up 18.89% year-over-year. In the year 2024, JD Health International had annual revenue of 58.16B with 8.65% growth.
Revenue (ttm)
65.11B CNY
Revenue Growth
+18.89%
P/S Ratio
2.73
Revenue / Employee
18.27M CNY
Employees
3,564
Market Cap
194.65B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 58.16B | 4.63B | 8.65% |
| Dec 31, 2023 | 53.53B | 6.79B | 14.54% |
| Dec 31, 2022 | 46.74B | 16.05B | 52.32% |
| Dec 31, 2021 | 30.68B | 11.30B | 58.30% |
| Dec 31, 2020 | 19.38B | 8.54B | 78.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 35.81B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |
| 3SBio | 9.94B |